GARNET: 98% SVR rates following eight-week treatment with ombitasvir/paritaprevir/ritonavir + dasabuvir for patients with HCV genotype 1b infection without cirrhosis

Authors
Category Primary study
ConferenceHepatology International
Year 2017
This article has no abstract
Epistemonikos ID: 2172ff0be391f8dc99bae4114eedc53811de2672
First added on: Apr 29, 2026